Fig. 3.

Cumulative number of days with PASI 100 from week 0 to 52. *Differences in the mean number of days with PASI 100 were statistically significant versus BKZ 320 mg Q4W/Q8W. Model: FE NMA. ADA adalimumab, BKZ bimekizumab, BRO brodalumab, CI confidence interval, ETN etanercept, FE fixed effects, GUS guselkumab, IL interleukin, IXE ixekizumab, NMA network meta-analysis, PASI 100 achievement of 100% improvement from baseline in Psoriasis Area and Severity Index, Q4W every 4 weeks, Q8W every 8 weeks, RZB risankizumab, SEC secukinumab, TNF tumour necrosis factor, UST ustekinumab